Liang Chunlan, Mu Xile, Bao Qinglan, Borzigin Pengsigerexi, Sheng Hongyan, Han Xiaomei, Chen Yingsong, Wang Tegexibaiyin
Mongolian Medicine College, Inner Mongolia Medical University, Hohhot, 010000, PR China.
Mongolian Medicine College, Inner Mongolia Minzu University, Tongliao, 028000, PR China.
J Ethnopharmacol. 2024 Jul 15;329:117854. doi: 10.1016/j.jep.2024.117854. Epub 2024 Apr 6.
Mammary gland hyperplasia, a prevalent benign breast condition, often serves as a precursor to various other breast diseases. He-Zi-3 soup (HZ-3), a traditional Mongolian remedy, is utilized for treating this condition.
To explore the effect and underlying mechanism of HZ-3, a Mongolian medicinal preparation, on mammary gland hyperplasia.
This study aimed to assess the impact of different doses of HZ-3 in a rat model of mammary hyperplasia. The active components within HZ-3 drug serum were identified and analyzed through network pharmacology and target prediction. To elucidate the underlying mechanism of HZ-3 in addressing mammary hyperplasia, we conducted a series of investigations on estradiol-induced mammary hyperplasia in model rates. Assessments included measurements of papilla width and height, hematoxylin and eosin staining, Masson staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), Western blot, and immunohistochemistry.
Our investigation revealed the identification of 21 compounds, primarily terpenoids, through serum medicinal chemistry screening. Utilizing network pharmacological analysis, we observed predominant regulation through the estrogen pathway, closely associated with key genes including esr1,esr2, ncoa1, krt 19, ctsd, ebag 9, and bcl-2. Assessments encompassing nipple height and width, histological examination, immunohistochemical analysis, and serum hormone levels via enzyme-linked immunosorbent assay demonstrated the inhibitory effect of HZ-3 on mammary hyperplasia in rat models. RT-qPCR and Western blot analyses corroborated these findings, affirming the suppression of mammary hyperplasia by HZ-3 through the activation of estrogen pathway signaling.
乳腺增生是一种常见的良性乳腺疾病，常是其他各种乳腺疾病的先兆。和子-3汤（HZ-3）是一种传统的蒙药制剂，用于治疗这种疾病。
探讨蒙药制剂HZ-3对乳腺增生的作用及其潜在机制。
本研究旨在评估不同剂量的HZ-3对乳腺增生大鼠模型的影响。通过网络药理学和靶点预测对HZ-3含药血清中的活性成分进行鉴定和分析。为阐明HZ-3治疗乳腺增生的潜在机制，我们对模型大鼠雌激素诱导的乳腺增生进行了一系列研究。评估包括乳头宽度和高度测量、苏木精-伊红染色、Masson染色、逆转录-定量聚合酶链反应（RT-qPCR）、蛋白质免疫印迹法和免疫组织化学。
我们的研究通过血清药物化学筛选鉴定出21种化合物，主要为萜类化合物。利用网络药理学分析，我们观察到主要通过雌激素途径进行调控，这与包括esr1、esr2、ncoa1、krt 19、ctsd、ebag 9和bcl-2在内的关键基因密切相关。通过乳头高度和宽度测量、组织学检查、免疫组织化学分析以及酶联免疫吸附测定血清激素水平等评估表明，HZ-3对大鼠模型中的乳腺增生具有抑制作用。RT-qPCR和蛋白质免疫印迹法分析证实了这些发现，肯定了HZ-3通过激活雌激素途径信号传导抑制乳腺增生。
